B-Type Natriuretic Peptide Is Effective Therapy before Care
Authors: Ronald Witteles, Kelly Matsuda, Michael B. Fowler
Journal: Annals of Internal Medicine (2004)

Letters7 December 2004B-Type Natriuretic Peptide Is Effective Therapy before CareRonald Witteles, MD, Kelly Matsuda, PharmD, and Michael B. Fowler, MB, FRCPRonald Witteles, MDFrom Stanford University School of Medicine, Stanford, CA 94305-5406.Search for more papers by this author, Kelly Matsuda, PharmDFrom Stanford University School of Medicine, Stanford, CA 94305-5406.Search for more papers by this author, and Michael B. Fowler, MB, FRCPFrom Stanford University School of Medicine, Stanford, CA 94305-5406.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-141-11-200412070-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note:The lead author of the following Clinical Observation was one of a dozen Associates of the American College of Physicians selected to present a clinical vignette at the 2004 Annual Session in Philadelphia. We are proud to present this case report through a special arrangement with the Council of Associates of the College.TO THE EDITOR:Background: B-type natriuretic peptide (BNP) is an endogenous hormone secreted by the ventricular myocardium in response to increased wall stretch. Actions of BNP include diuresis, natriuresis, and vasodilatation of both the systemic and pulmonary vascular systems. Recombinant BNP (nesiritide) is given as a ...References1. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized, controlled trial. JAMA. 2002;287:1531-40. [PMID: 11911755] MedlineGoogle Scholar2. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999;34:155-62. [PMID: 10400005] CrossrefMedlineGoogle Scholar3. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-53. [PMID: 10911006] CrossrefMedlineGoogle Scholar4. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-75. [PMID: 1944425] CrossrefMedlineGoogle Scholar5. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102-8. [PMID: 12486437] CrossrefMedlineGoogle Scholar6. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803. [PMID: 11869844] CrossrefMedlineGoogle Scholar7. Hill JA, Hsu K, Pauly DF, Schofield R, Aranda JM. Sustained use of nesiritide to aid in bridging to heart transplant. Clin Cardiol. 2003;26:211-4. [PMID: 12769247] CrossrefMedlineGoogle Scholar8. Cargill RI, Lipworth BJ. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest. 1996;110:1220-5. [PMID: 8915224] CrossrefMedlineGoogle Scholar9. Bhat G, Costea A. Reversibility of medically unresponsive pulmonary hypertension with nesiritide in a cardiac transplant recipient. ASAIO J. 2003;49:608-10. [PMID: 14524574] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Ronald Witteles, MD; Kelly Matsuda, PharmD; Michael B. Fowler, MB, FRCPAffiliations: From Stanford University School of Medicine, Stanford, CA 94305-5406. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Rise And Fall Of Natrecor For Congestive Heart Failure: Implications For Drug Policy 7 December 2004Volume 141, Issue 11Page: 895KeywordsBrain natriuretic peptidesCardiac transplantationHeart failureHemodynamicsNatriuretic peptidesPulmonary arteriesPulmonary vascular resistanceTransplantationVasodilationVasodilators ePublished: 7 December 2004 Issue Published: 7 December 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...